Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 8/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16879490 | 0.80 | KMT2A (0.58) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL29349427 | 0.77 | GLS (0.51) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL17223881 | 0.77 | GLS (0.51) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL16879486 | 0.76 | CA1 (0.39) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL16887495 | 0.76 | MKNK1 (0.40) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL16879424 | 0.76 | GLS (0.44) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL16887483 | 0.75 | KMT2A (0.68) | RAB9AGAAMETDEGS1HTT | |
| SCHEMBL21907303 | 0.74 | GAA (0.53) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL4037192 | 0.73 | LMNA (0.56) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL18135203 | 0.72 | L3MBTL1 (0.56) | GLSRAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112920180-A | Glutaminase inhibitors | 理森制药股份公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-105960405-B | Glutaminase inhibitors | 理森制药股份公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3092235-A2 | NOVEL INHIBITORS OF GLUTAMINASE | Rhizen Pharmaceuticals S.A. (CH) | 2016-11-16 | — | — | EP | disclosed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| WO-2015101958-A2 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS SA (CH) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015101958-A2 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS SA (CH) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | CA1 2420/4885CA2 1799/4885CA5A 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.